2-(2,2-dicyclohexylethyl)piperidine

• ChemBase ID: 945
• Molecular Formular: C19H35N
• Molecular Mass: 277.4879
• Monoisotopic Mass: 277.27695013
• SMILES: N1C(CC(C2CCCCC2)C2CCCCC2)CCCC1
• Canonical SMILES: C1CCC(NC1)CC(C1CCCCC1)C1CCCCC1
• InChI: InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
• InChIKey: CYXKNKQEMFBLER-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-(2,2-dicyclohexylethyl)piperidine
• IUPAC Traditional name: @perhexiline; perhexiline
• Synonyms: Perhexilina [INN-Spanish]; Perhexilinum [INN-Latin]; 2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; (+)-2-(2,2-Dicyclohexylethyl)piperidine; Perhexilene; Perhexilline; Perhexiline

Database IDs

• CAS Number: 6621-47-2
• PubChem SID: 160964408; 46504471
• PubChem CID: 4746
• CHEBI ID: 35553
• ATC CODE: C08EX02
• CHEMBL: 75880
• Chemspider ID: 4584
• DrugBank ID: DB01074
• KEGG ID: D08340
• Unique Ingredient Identifier: KU65374X44
• Wikipedia Title: Perhexiline

CALCULATED PROPERTIES

JChem

• H Acceptors: 1
• H Donor: 1
• LogD (pH = 5.5): 2.2955542
• LogD (pH = 7.4): 2.6224937
• Log P: 5.5313087
• Molar Refractivity: 87.2286 cm^3
• Polarizability: 35.12344 Å^3
• Polar Surface Area: 12.03 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 5.87
• LOG S: -7.01
• Solubility (Water): 2.72e-05 g/l

PROPERTIES

Physical Property

• Solubility: 0.0608 mg/L
• Hydrophobicity(logP): 6.2

Pharmacology Properties

• Admin Routes: Oral
• Bioavailability: Dose Dependent
• Half Life: Dose Dependent
• Metabolism: Saturable Hepatic

DETAILS

DrugBank - DB01074

• Drug Groups: approved
• Description: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [PubChem]
• Indication: For the management of severe angina pectoris.
• Pharmacology: Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.
• Toxicity: Oral LD₅₀ rat: 2150 mg/kg; Oral LD₅₀ Mouse: 2641 mg/kg. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).
• Affected Organisms: Humans and other mammals
• Biotransformation: The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6).
• Absorption: Well absorbed (>80%) from the gastrointestinal tract following oral administration.
• Half Life: Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.
• Protein Binding: Perhexiline and its metabolites are highly protein bound (>90%).
• External Links: Wikipedia